Search research articles
Contact Us
Filters
Showing results (311-320 of 354) with videos related to
Page
of 36
Sort By:
The Medical Journal of Australia
|
June 26, 2023
Patterns of care for people with small cell lung cancer in Victoria, 2011-19: a retrospective, population-based registry data study
Joanna Huang, Wasek Faisal, Margaret Brand, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 30, 2023
Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso
Nicholas McNamee, Catriona Harvey, Lauren Gray, et al.
Nature Communications
|
February 28, 2024
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE
Lavinia Tan, Chris Brown, Antony Mersiades, et al.
The New England Journal of Medicine
|
June 5, 2023
Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLC
Masahiro Tsuboi, Roy S Herbst, Thomas John, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 22, 2019
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study
Enriqueta Felip, Filippo G de Braud, Michela Maur, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 26, 2023
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
Thomas John, Christian Grohé, Jonathan W Goldman, et al.
JTO Clinical and Research Reports
|
June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLC
Alexander Drilon, Chao-Hua Chiu, Yun Fan, et al.
Cancer Cell
|
April 30, 2013
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP
Min Lu, Hilde Breyssens, Victoria Salter, et al.
The Lancet. Oncology
|
September 5, 2020
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
Anna K Nowak, W Joost Lesterhuis, Peey-Sei Kok, et al.
Targeted Oncology
|
March 11, 2024
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Masahiro Tsuboi, Roy S Herbst, Thomas John, et al.
Page
of 36
Search research articles
Search
Showing results (311-320 of 354) with videos related to
Sort By:
Page
of 36
The Medical Journal of Australia
|
June 26, 2023
Patterns of care for people with small cell lung cancer in Victoria, 2011-19: a retrospective, population-based registry data study
Joanna Huang, Wasek Faisal, Margaret Brand, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 30, 2023
Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso
Nicholas McNamee, Catriona Harvey, Lauren Gray, et al.
Nature Communications
|
February 28, 2024
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE
Lavinia Tan, Chris Brown, Antony Mersiades, et al.
The New England Journal of Medicine
|
June 5, 2023
Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLC
Masahiro Tsuboi, Roy S Herbst, Thomas John, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 22, 2019
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study
Enriqueta Felip, Filippo G de Braud, Michela Maur, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 26, 2023
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
Thomas John, Christian Grohé, Jonathan W Goldman, et al.
JTO Clinical and Research Reports
|
June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLC
Alexander Drilon, Chao-Hua Chiu, Yun Fan, et al.
Cancer Cell
|
April 30, 2013
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP
Min Lu, Hilde Breyssens, Victoria Salter, et al.
The Lancet. Oncology
|
September 5, 2020
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
Anna K Nowak, W Joost Lesterhuis, Peey-Sei Kok, et al.
Targeted Oncology
|
March 11, 2024
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Masahiro Tsuboi, Roy S Herbst, Thomas John, et al.
Page
of 36